Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dong Qu

Showing results (221-230 of 222) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 222 results.
BJS Open|September 20, 2022
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world studyWei-Feng Qu, Zhen-Bin Ding, Xu-Dong Qu, et al.
Nature Communications|January 20, 2024
Macro CD5L<sup>+</sup> deteriorates CD8<sup>+</sup>T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinomaJia-Cheng Lu, Lei-Lei Wu, Yi-Ning Sun, et al.
Pageof 23

Showing results (221-230 of 222) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 222 results.
BJS Open|September 20, 2022
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world studyWei-Feng Qu, Zhen-Bin Ding, Xu-Dong Qu, et al.
Nature Communications|January 20, 2024
Macro CD5L<sup>+</sup> deteriorates CD8<sup>+</sup>T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinomaJia-Cheng Lu, Lei-Lei Wu, Yi-Ning Sun, et al.
Pageof 23